VANCOUVER, BC — November 11, 2025 — Leads & Copy — VVT Med Inc. (TSXV: VVTM), a leader in minimally invasive vein treatment solutions, has announced several milestones in its global expansion, sales, and capital strategies.
The company has entered into a five-year distribution agreement with Medworks India, a healthcare distributor, for its ScleroSafe™ medical device in the varicose vein treatment market, effective September 5, 2025. Medworks India is committed to purchasing CAD $3.7 million worth of ScleroSafe™ units over the five-year period, with CAD $1.85 million under a “Buy & Pay” model, subject to early termination of the Distribution Agreement. VVT Med’s ScleroSafe™ received regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) in India in 2022.
The agreement can be terminated for cause by VVT Med, including payment defaults, failure to meet obligations or sales targets, legal changes, IP disputes, or certain organizational changes within Medworks India. Either party may also terminate the agreement for convenience with 30 days’ notice.
Following successful procedures across key vein centers, physician satisfaction has been high, resulting in confirmed reorders. Medworks has placed its initial stocking order, marking the beginning of commercial rollout and physician adoption across India.
VVT Med Inc. CEO Erez Tetro said the partnership underscores Medworks India’s confidence in the commercial potential of ScleroSafe™ and reflects accelerating demand for the company’s venous-care solution.
VVT Med, in collaboration with Promedika, has completed 150 ScleroSafe™ treatments in North Macedonia. The procedures provide evidence of efficacy under the product’s European Union CE certification and mark a step toward broader adoption across the European Economic Area (EEA). The milestone reflects recurring orders from the treating clinic, indicating consistent physician use and positive patient outcomes. Promedika has placed replenishment orders and expects further orders as adoption continues to grow.
Dr. Sasko Nikolov, an Interventional Cardiologist, has expanded the use of ScleroSafe™ in advanced and complex venous cases.
Dr. Nikolov said ScleroSafe is his preferred technology for treating varicose veins, particularly in complex cases such as ulcers, recurrences, and advanced disease.
VVT Med intends to issue 320,000 common shares at CAD$0.56 per share for advisory services rendered in connection with its public listing. The company also intends to enter into agreements with vendors to settle up to CAD$720,197 of outstanding indebtedness through the issuance of up to 1,745,151 common shares at CAD$0.31 per share.
The issuance of shares is subject to approval by the TSX Venture Exchange. The shares will be subject to a statutory hold period of four months and one day, in accordance with applicable securities laws and TSXV policies. Completion of the debt settlement remains conditional upon the execution of definitive agreements and receipt of final approval from the TSXV.
VVT Medical develops, manufactures, and distributes minimally invasive solutions for the treatment of vein diseases, starting with varicose veins. VVT’s FDA-cleared and CE-marked catheter-based technologies, ScleroSafe and V-Block, enable safe, office-based procedures with no anesthesia, no downtime, and minimal pain and side effects.
Erez Tetro, Chief Executive Officer
Source: VVT Med Inc.
